TX-MAVENIR
14.12.2020 15:02:13 CET | Business Wire | Press release
Mavenir, the industry’s only end-to-end cloud-native network software provider for mobile operators, and Microelectronics Technology Inc. (MTI), a network solutions provider, announced today the general availability of the Evenstar B3 Remote Radio Head (RRH) in collaboration with Facebook Connectivity. The Evenstar B3 RRH will give mobile network operators (MNOs) the ability to accelerate the adoption of Open RAN technology by providing standardized architecture and a modular approach for disaggregated Radio Access Network (RAN) components.
Mavenir and MTI recently completed the end-to-end interoperability testing of the Evenstar B3 RRH and are now lab testing the solution with multiple MNOs around the world. The Evenstar B3 RRH from Mavenir and MTI not only addresses current feature requirements in networks today, but also provides flexibility for future feature upgrades, providing a true Virtualized RAN (vRAN) solution.
Launched earlier this year, the Evenstar program focuses on building general-purpose RAN reference architecture for 4G and 5G networks that are aligned with 3GPP and O-RAN specifications. The Evenstar program also contributes to the Telecom Infra Project (TIP)’s OpenRAN Project Group, working to accelerate the path to commercial deployment of simplified, flexible, disaggregated RAN technologies. RRHs, distribution units (DU), and control unit (CU) software have traditionally been only available as a packaged unit, limiting opportunities to serve suburban and rural locations. By decoupling these components, the Evenstar program enables MNOs to choose best-in-class technology and deploy solutions from an increasing number of technology partners.
“The availability of low cost RRHs based on OpenRAN specifications is key to faster adoption of OpenRAN. We are excited to work with Facebook, TIP and MTI to bring the first 4G/5G OpenRAN-compliant Evenstar radio to market that is generally available for use by the Open RAN community.” said Pardeep Kohli, President & CEO of Mavenir.
“MTI is excited to announce the general availability of the Evenstar RRH. This is a major milestone for MTI and for our partners in the Open RAN ecosystem. We will continue to introduce more products to the Open RAN market and address the needs of different regions.” said Allen Yen, Chairman & CEO of MTI.
The Evenstar B3 RRH is generally available now as part of the Evenstar program, with plans to expand into other Open RAN architectural elements. The Evenstar program will eventually include multiple RRH product SKUs, including FDD B3 (4T4R 4X40W). The RRH architecture is based on O-RAN Alliance Fronthaul specifications based on Split 7.2.
About MTI
Microelectronics Technology Inc. (MTI) is a high-technology company that has specialized in wireless communication product development, manufacturing, and global sales for more than 35 years. Based on core competency in RF/ Microwave, MTI has established a leading position in the fields of Remote Radio Heads, Microwave Radios, Satellite Transceivers and ODUs, Broadband Wireless access products, and Radio Frequency Identification (RFID) readers and modules. With this excellent record of accomplishment, MTI has established valued, long-term partnerships with world-leading partners. MTI now offers a portfolio of products that are O-RAN compliant. For more information, visit: www.mtigroup.com
About Mavenir
Mavenir is the industry's only end-to-end, cloud-native Network Software and Solutions/Systems Integration Provider, focused on accelerating software network transformation for Communications Service Providers (CSPs). Mavenir offers a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging innovations in IMS (VoLTE, VoWiFi, Advanced Messaging (RCS)), Private Networks as well as vEPC, 5G Core and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 120 countries, which serve over 50% of the world’s subscribers.
Mavenir embraces disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. For more information, visit: www.mavenir.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005169/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Inspirit Capital to Acquire Kaplan Languages Group20.4.2026 17:15:00 CEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, is pleased to announce its plans to acquire KLG Kaplan Languages Group (“KLG”), a leading global language education platform, from Kaplan. All conditions for the sale have been met, and completion is due to take place on 1 May. KLG comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Since 2006, KLG has provided high-quality language education, supporting students in achieving their language goals through academic excellence, cultural immersion, and life-changing experiences. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. This next phase of ownership will also see the development of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. Paul Youens, Investment Director, Inspirit Capital: “KLG has built a st
Cleaner by Design: SaniSure Introduces PETG PharmaTainer™ Ultra-Clean Bottles & Carboys20.4.2026 16:00:00 CEST | Press release
Industry’s most widely adopted PETG material meets industry-leading cleanliness, compliance, and RNase/DNase-free validation—now available across the full bioprocessing workflow. SaniSure® today announced the launch of PETG PharmaTainer™, a new line of bioprocessing bottles and carboys combining widely accepted, medical-grade Eastman Eastar® PETG 6763 resin (DMF#9987) with SaniSure’s proprietary process and advanced automation. This launch expands SaniSure’s established PharmaTainer® platform—extending its proven cleanliness, robustness, and performance attributes to include industry-standard PETG alongside its existing PET and PC offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420641769/en/ PETG PharmaTainer™ bottles and carboys—RNase/DNase-free, ultra-clean, ready-to-use containers for bioprocessing applications. Available in volumes from 10 mL stability vials to 10 L carboys — in sterile (gamma-irradiated) an
Leaders of Dubai-Based Unicorns Hail City as Global Innovation Hub Shaping Future Technology and Driving the Digital Economy20.4.2026 15:08:00 CEST | Press release
Leaders of Dubai-based unicorn companies have reaffirmed the emirate’s status as a global hub for digital innovation and technology-led growth. The senior executives highlighted Dubai’s forward-looking regulatory environment, advanced infrastructure, and ability to attract international talent as key factors strengthening its appeal for high-growth digital businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420503062/en/ Leaders of Dubai-based unicorns hail city as global innovation hub shaping future technology and driving the digital economy (Photo: AETOSWire) They noted that Dubai has evolved into a strategic launchpad for ambitious companies, offering an agile business environment that supports innovation and enables expansion into regional and international markets. The business leaders also praised the strong alignment between the public and private sectors within Dubai’s digital ecosystem, supported by Dubai
Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 15:00:00 CEST | Press release
– Highly innovative and original gameplay earns strong reception from players around the globe – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broade
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
